Faye Reiff-Pasarew, MD
Article
Semaglutide reduces major adverse cardiovascular events by 20% in patients with cardiovascular disease
June 3, 2024
Clinical question: Does semaglutide reduce cardiovascular events in non-diabetics with cardiovascular disease? Background: While glucagon-like peptide-1 (GLP-1) agonists reduce cardiovascular events...